Business Wire

CA-TALKDESK-INC

14.7.2021 15:02:06 CEST | Business Wire | Press release

Share
German Solar Company Zolar Chooses Talkdesk to Power Contact Center Solution

Talkdesk®, Inc. , the global customer experience leader for customer-obsessed companies, has been selected by Zolar , a Berlin-based green tech company, as its contact center provider. Talkdesk will supply voice services and Talkdesk for Salesforce™ to the Zolar team of solar energy advisers, enabling them to provide more streamlined interactions with customers while leveraging and maintaining a comprehensive view of the customer journey.

Zolar is the brainchild of founder Alex Melzer, who gained inspiration for starting the company after embarking on a 2,600km bicycle ride across South America in 2015. Moved by the scenes of man-made climate change, which he observed along the way, Melzer became determined to make a difference. He set up Zolar the following year with a mission to create a future powered by clean energy. The company now offers a range of products for customers to generate affordable and environmentally friendly electricity.

Zolar employs a team of solar experts who advise customers throughout all phases of the purchasing process, from initial inquiry to the creation of a rooftop solar energy solution tailored to the unique needs of each customer. With Talkdesk CX Cloud™ , an end-to-end customer experience solution, Zolar can quickly and easily field their typical daily volume of more than 1,000 customer calls, even when staff work from home. Through the solution’s deep integration with Salesforce, they can also access and maintain a complete view of each customer engagement to further personalize the experiences.

“We needed a solution with advanced routing capabilities and a view into call behaviour,” said Markus Schaffrinski, Chief Technology Officer, Zolar. “Talkdesk CX Cloud gives us a sophisticated, yet simple-to-use tool with smart routing right out of the box. By allowing us to respond more efficiently, from anywhere, and provide a better overall experience, our customers can come away not only feeling good about choosing a clean energy solution, they also feel added confidence in having entrusted Zolar to power it.”

“The fast growth of Zolar is rooted in its passion for the environment and focus on delivering the highest quality product and service. They exemplify the magic that happens when purpose truly drives execution,” said Tiago Paiva, chief executive officer and founder, Talkdesk. “As more households throughout Europe turn to green energy, Talkdesk looks forward to supporting their mission with advanced contact center tools for helping Zolar deliver more great customer experiences.”

Additional Resources

Social Networks

About Talkdesk

Talkdesk® is a global customer experience leader for customer-obsessed companies. Our contact center solution provides a better way for businesses and customers to engage with one another. Our speed of innovation and global footprint reflect our commitment to ensure businesses everywhere can deliver better customer experiences through any channel, resulting in higher customer satisfaction, cost savings and profitability. Talkdesk CX CloudTM is an end-to-end customer experience solution that combines enterprise scale with consumer simplicity. Over 1,800 innovative companies around the world, including IBM, Acxiom, Trivago, and Fujitsu partner with Talkdesk to deliver a better way to great customer experience. Learn more and request a demo at www.talkdesk.com .

About Zolar

The greentech company Zolar offers photovoltaic systems, which homeowners are able to custom plan, compare and order online, at a fixed price. By means of the Zolar online configurator, homeowners are able to customize the components of their solar energy system according to their needs and will receive a personal consultation at the same time from one of our solar energy experts. Zolar has a broad network of local partner companies that install the systems on-site. The Berlin-based start-up employs 190 people and pursues the vision of installing a solar system on every roof worldwide to enable the independence of private households from the public power grid. Zolar empowers its customers to promote the energy turnaround, to reduce the CO2 footprint and thus make an effective contribution to climate protection. www.zolar.de

Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks ™ or registered ® trademarks of their respective holders. Use of them does not imply any affiliation or endorsement by them.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye